MyETF.app
HomeUS Marketequity › CNCR

CNCR — Range Cancer Therapeutics ETF

Range Cancer Therapeutics ETF (ticker: CNCR) is a equity ETF issued by Exchange Traded Concepts tracking Range Oncology Therapeutics Index. It was launched on 2015-10-13.

Live Price
Change
AUM
Expense Ratio0.01%
Avg Volume

Returns (Total Return)

PeriodReturn
1 Day0.00%
1 Week0.00%
1 Month-11.31%
3 Months-16.87%
6 Months-36.25%
YTD-26.73%
1 Year-38.81%
3 Years-36.83%
5 Years
10 Years
Since Inception

Top Holdings

#SecuritySymbolWeight
1 GERON CORP GERN 3.99%
2 GERON CORP GERN 3.99%
3 SUMMIT THERAPEUTICS INC SMMT 3.83%
4 SUMMIT THERAPEUTICS INC SMMT 3.83%
5 SUMMIT THERAPEUTICS INC SMMT 3.83%
6 SUMMIT THERAPEUTICS INC SMMT 3.83%
7 SUMMIT THERAPEUTICS INC SMMT 3.83%
8 GERON CORP GERN 3.80%
9 GERON CORP GERN 3.80%
10 GERON CORP GERN 3.80%

Fund Profile

IssuerExchange Traded Concepts
BrandRange
Asset Classequity
StrategyEqual
StructureETF
CategoryHealth & Biotech Equities
SegmentEquity: Global Pharma, Biotech & Life Sciences
RegionDeveloped Markets
Index TrackedRange Oncology Therapeutics Index
Inception Date2015-10-13

Quick Facts

TickerCNCR
Full NameRange Cancer Therapeutics ETF
IssuerExchange Traded Concepts
Asset Classequity
Expense Ratio0.01%
Inception2015-10-13
Index TrackedRange Oncology Therapeutics Index

Frequently Asked Questions

What does CNCR track?

CNCR (Range Cancer Therapeutics ETF) tracks Range Oncology Therapeutics Index, a equity benchmark.

What is the expense ratio of CNCR?

CNCR has an expense ratio of 0.01% per year.

What is the AUM of CNCR?

Assets under management for CNCR are reported by Exchange Traded Concepts and updated regularly on this page.

Does CNCR pay a dividend?

CNCR distributes income according to its prospectus. Check the dividend history tab for ex-dividend dates and yield.

Who issues CNCR?

CNCR is issued by Exchange Traded Concepts under the Range brand, launched on 2015-10-13.

Open the interactive CNCR dashboard for charts, historical fund flows, holdings breakdown and seasonality patterns.